14 RESULTS
COMMENT This was a milestone in several respects, as aducanumab is the first novel therapy approved for Alzheimer’s in 18 years and the first drug attacking one aspect of the underlying pathobiology. This was an extremely difficult judgment to make. I take the ...
COMMENT We were extremely disappointed to learn about the early worsening of some cognitive measures in our research participants and the need to discontinue testing of the BACE1 inhibitor CNP520 (umibecestat) in our Alzheimer’s Prevention Initiative (API) ...
COMMENT This is obviously disappointing news for all stakeholders. Some things that we are reflecting on include the fact that, for drugs of this type, there is the conundrum of having to have elevated brain amyloid (and thus having had AD pathology for many ...
COMMENT Yet another major contribution from DIAN. The investigators conducted a comprehensive longitudinal biomarker study in volunteers around the world who do or do not have autosomal dominant mutations that cause onset of Alzheimer’s symptoms at a generally ...
COMMENT The Eli Lilly/AstraZeneca decision to discontinue the global Phase 3 trials of lanabacestat was a disappointment, but, in view of similar decisions by Merck, perhaps not a complete surprise. Both of the lanabecestat programs enrolled persons with early ...
COMMENT As the authors state carefully and clearly, these findings need to be replicated, the analytic methods need to be confirmed, ROC performance in other brain diseases is needed, and validation in clinical trials of AB lowering agents is needed. That said, ...
COMMENT I first met Allen when he and I shared the stage in the 1990s for a regional update on Alzheimer’s disease not long after the ApoE4 risk story surfaced. After his talk, a woman in the audience asked if he knew his genotype. He spent five minutes regaling ...
COMMENT This strikes me as a creative way to deliver a potent class of therapeutics for a host of neurodegenerative diseases, exactly as the authors suggest. HDAC inhibitors have been a drug discovery/development class of intense scrutiny for many years and, from ...
COMMENT In response to Lon Schneider: Agitation is one of the most disabling features of AD and other dementias, compromising the quality of life of both patients and care providers. It is a common cause of institutionalization in the United States and is ...
COMMENT There appear to be major differences in the quality of the stained images between the two papers, suggesting perhaps that the reasons lie in the particular staining technique used (Bennhold's technique used by Goldstein et al. and Moncaster et al. vs ...
COMMENT I applaud Howard et al. for attempting a clinical trial that has great potential public health significance. I and surely others also appreciate the support provided by the Medical Research Council. As part of a team committed to caring for and studying ...
COMMENT We are so grateful for the interest of the New York Times in the efforts of the Alzheimer's Prevention Initiative. Their coverage also means a great deal to Dr. Francisco Lopera, the pioneer who has identified the families afflicted with early onset ...
COMMENT I was involved with this work as chairman of the Data and Safety Monitoring Committee, so I will not comment on the trial specifically but offer a general perspective here. There is a modest amount of information from placebo-controlled trials in patients ...
COMMENT My simplified view is that the study was unable to answer the main questions that it posed, so it is largely uninformative with respect to effectiveness outcomes. That having been said, the study at least suggests that the effectiveness of these agents is ...
